T1	Participants 60 92	anti-herpes virus therapy in MS.
T2	Participants 204 305	patients with relapsing-remitting MS in a phase 2, randomized, double-blind, placebo-controlled study
T3	Participants 443 559	Patients were eligible for the study if they had had two or more MS relapses in the 2-year period before enrollment.
T4	Participants 560 750	Seventy patients with Expanded Disability Status Scale scores of 0 to 5.5 were randomly assigned to receive 1 gram of valacyclovir (n = 36) or placebo (n = 34) three times daily for 24 weeks
T5	Participants 1892 1991	patients with relapsing-remitting MS who had two or more relapses during the previous 2-year period
T6	Participants 2397 2461	patients with MS and high levels of MRI-evident disease activity
